Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

90 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Sexuality and cancer: conversation comfort zone.
Penson RT, Gallagher J, Gioiella ME, Wallace M, Borden K, Duska LA, Talcott JA, McGovern FJ, Appleman LJ, Chabner BA, Lynch TJ Jr. Penson RT, et al. Among authors: appleman lj. Oncologist. 2000;5(4):336-44. doi: 10.1634/theoncologist.5-4-336. Oncologist. 2000. PMID: 10965002 Free article.
Molecular Subtypes Improve Prognostic Value of International Metastatic Renal Cell Carcinoma Database Consortium Prognostic Model.
de Velasco G, Culhane AC, Fay AP, Hakimi AA, Voss MH, Tannir NM, Tamboli P, Appleman LJ, Bellmunt J, Kimryn Rathmell W, Albiges L, Hsieh JJ, Heng DY, Signoretti S, Choueiri TK. de Velasco G, et al. Among authors: appleman lj. Oncologist. 2017 Mar;22(3):286-292. doi: 10.1634/theoncologist.2016-0078. Epub 2017 Feb 20. Oncologist. 2017. PMID: 28220024 Free PMC article.
Phase I clinical trial of the farnesyltransferase inhibitor BMS-214662 administered as a weekly 24 h continuous intravenous infusion in patients with advanced solid tumors.
Eder JP Jr, Ryan DP, Appleman L, Zhu AX, Puchalski T, He X, Sonnichsen DS, Cooper M, Wright J, Clark JW, Supko JG. Eder JP Jr, et al. Cancer Chemother Pharmacol. 2006 Jul;58(1):107-16. doi: 10.1007/s00280-005-0134-0. Epub 2005 Dec 13. Cancer Chemother Pharmacol. 2006. PMID: 16362299 Clinical Trial.
A phase I study of foretinib, a multi-targeted inhibitor of c-Met and vascular endothelial growth factor receptor 2.
Eder JP, Shapiro GI, Appleman LJ, Zhu AX, Miles D, Keer H, Cancilla B, Chu F, Hitchcock-Bryan S, Sherman L, McCallum S, Heath EI, Boerner SA, LoRusso PM. Eder JP, et al. Among authors: appleman lj. Clin Cancer Res. 2010 Jul 1;16(13):3507-16. doi: 10.1158/1078-0432.CCR-10-0574. Epub 2010 May 14. Clin Cancer Res. 2010. PMID: 20472683 Clinical Trial.
Phase I and pharmacokinetic study of the dolastatin-15 analogue tasidotin (ILX651) administered intravenously on days 1, 3, and 5 every 3 weeks in patients with advanced solid tumors.
Cunningham C, Appleman LJ, Kirvan-Visovatti M, Ryan DP, Regan E, Vukelja S, Bonate PL, Ruvuna F, Fram RJ, Jekunen A, Weitman S, Hammond LA, Eder JP Jr. Cunningham C, et al. Among authors: appleman lj. Clin Cancer Res. 2005 Nov 1;11(21):7825-33. doi: 10.1158/1078-0432.CCR-05-0058. Clin Cancer Res. 2005. PMID: 16278405 Clinical Trial.
Phase I trial of oral MAC-321 in subjects with advanced malignant solid tumors.
Lockhart AC, Bukowski R, Rothenberg ML, Wang KK, Cooper W, Grover J, Appleman L, Mayer PR, Shapiro M, Zhu AX. Lockhart AC, et al. Cancer Chemother Pharmacol. 2007 Jul;60(2):203-9. doi: 10.1007/s00280-006-0362-y. Epub 2006 Nov 8. Cancer Chemother Pharmacol. 2007. PMID: 17091249 Clinical Trial.
90 results